Rodman & Renshaw Initiates Coverage on Tharimmune (NASDAQ:THAR)

Rodman & Renshaw assumed coverage on shares of Tharimmune (NASDAQ:THAR) in a report released on Friday morning,Benzinga reports. The firm issued a buy rating and a $17.00 target price on the stock.

Tharimmune Trading Up 10.8 %

Shares of THAR opened at $2.25 on Friday. The stock has a fifty day moving average price of $2.29 and a two-hundred day moving average price of $2.98. Tharimmune has a 52-week low of $1.84 and a 52-week high of $9.79.

Hedge Funds Weigh In On Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned about 2.06% of Tharimmune as of its most recent SEC filing. Hedge funds and other institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).